advanced-therapies — source conflicts (round 5)

Conflict: [FDA Dupixent label, 2026] licenses dupilumab from 6 months for moderate-to-severe AD. [EMA Dupixent EPAR, accessed 2026-10-03] licenses it in children 6 months–11 years for severe AD only. Unresolved — add to open_questions.

Conflict: [EMA Olumiant EPAR, accessed 2026-10-03] licenses oral baricitinib for moderate-to-severe AD in children from 2 years. [FDA Olumiant label, 2026] gives baricitinib no AD indication at any age. Unresolved — add to open_questions.

Conflict: [FDA Opzelura label, 2026] licenses ruxolitinib cream for AD from age 2. [EMA Opzelura EPAR, accessed 2026-10-03] licenses it for AD in adults only. Unresolved — add to open_questions.

Conflict: [FDA Eucrisa label, 2025] says crisaborole is licensed for mild-to-moderate AD from 3 months. [EMA Staquis EPAR, 2022] says the EU authorisation (from 2 years) was withdrawn in January 2022, never marketed. Unresolved for UK — add to open_questions.